High-dose immunosuppressive therapy with autologous hematopoietic stem cell transplantation as a treatment option in multiple sclerosis

Experimental Hematology

Volumn 36, Issue 8, 2008, Pages 922-928

  Shevchenko, Yury L ^a   Novik, Andrei A ^a   Kuznetsov, Aleksey N ^a   Afanasiev, Boris V ^b   Lisukov, Igor A ^c   Kozlov, Vladimir A ^c   Rykavicin, Oleg A ^d   Ionova, Tatyana I ^e   Melnichenko, Vladimir Y ^a   Fedorenko, Denis A ^a   Kulagin, Alexander D ^c   Shamanski, Sergei V ^d   Ivanov, Roman A ^a   Gorodokin, Gary ^f  

^a Pirogov National Medical Surgical Center   (Russian Federation)

^b PAVLOV FIRST SAINT PETERSBURG STATE MEDICAL UNIVERSITY   (Russian Federation)

^c INSTITUTE OF CLINICAL IMMUNOLOGY   (Russian Federation)

^d Ministry of Defense of the Russian Federation   (Russian Federation)

^e Center of the Quality of Life   (Russian Federation)

^f New Jersey Center for Quality of Life and Health Outcome Research   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; CARMUSTINE; CIPROFLOXACIN; CYCLOPHOSPHAMIDE; CYTARABINE; ETOPOSIDE; FLUCONAZOLE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IMMUNOGLOBULIN; MELPHALAN; THYMOCYTE ANTIBODY;

ADULT; ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; CLINICAL ARTICLE; CLINICAL TRIAL; DEATH; DISABILITY; DISEASE COURSE; DISEASE FREE SURVIVAL; DRUG MEGADOSE; ENTEROPATHY; EXPANDED DISABILITY STATUS SCALE; FEBRILE NEUTROPENIA; FEMALE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LIVER TOXICITY; MALE; MULTIPLE SCLEROSIS; NEUROIMAGING; NEUROLOGIC DISEASE; NEUROLOGIC EXAMINATION; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROSPECTIVE STUDY; SEPSIS; SURVIVAL RATE; SURVIVAL TIME; TREATMENT OUTCOME;

ADOLESCENT; ADULT; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; RUSSIA; TRANSPLANTATION, AUTOLOGOUS; TREATMENT OUTCOME;

EID: 47149098599     PISSN: 0301472X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.exphem.2008.03.001     Document Type: Article

References (27)

1. Martin R., McFarland H.F., and McFarlin D.E. Immunological aspects of demyelinating diseases. Annu Rev Immunol 10 (1992) 153-187
2. Noseworthy J.H., Lucchinetti C., Rodriguez M., and Weinshenker B.G. Multiple sclerosis. N Engl J Med 343 (2000) 938-952
3. Muraro P.A., McFarland H.F., and Martin R. Immunological aspects of multiple sclerosis with emphasis on the potential use of autologous haemopoietic stem cell transplantation. In: Burt R.K., and Marmont A.M. (Eds). Stem cell therapy for autoimmune disease (2004), Landes Bioscience, Georgetown, TX 277-283
4. Fassas A., Anagnostopoulos A., Kazis A., et al. Peripheral blood stem cell transplantation in the treatment of progressive multiple sclerosis: first results of a pilot study. Bone Marrow Transplant 20 (1997) 631-638
5. Burt R.K., Traynor A.E., Cohen B., et al. T cell-depleted autologous hematopoietic stem cell transplantation for multiple sclerosis: report on the first three patients. Bone Marrow Transplant 21 (1998) 537-541
6. Fassas A., Anagnostopoulos A., Kazis A., et al. Autologous stem cell transplantation in progressive multiple sclerosis-an interim analysis of efficacy. J Clin Immunol 20 (2000) 24-30
7. Fassas A., Passweg J.R., Anagnostopoulos A., et al. Haematopoietic stem cell transplantation for multiple sclerosis. A retrospective multicenter study. J Neurol 249 (2002) 1088-1097
8. Kozak T., Havrdova E., Pit'ha J., et al. High-dose immunosuppressive therapy with PBPC support in the treatment of poor risk multiple sclerosis. Bone Marrow Transplant 25 (2000) 525-531
9. Openshaw H., Lund B., Kashyap A., et al. Peripheral blood stem cell transplantation in multiple sclerosis with busulfan and cyclophosphamide conditioning report of toxicity and immunological monitoring. Biol Blood Marrow Transplant 25 (2000) 525-575
10. Burt R.K., Cohen B.A., Russell E., et al. Hematopoietic stem cell transplantation for progressive multiple sclerosis; failure of a total body irradiation-based conditioning regimen to prevent disease progression in patients with high disability scores. Blood 102 (2003) 2373-2378
11. Fassas A., and Nash R. Multiple sclerosis. Best Pract Res Clin Hematol 17 (2004) 247-262
12. Nash R.A., Bowen J.D., McSweeney P.A., et al. High-dose immunosuppressive therapy and autologous peripheral blood stem cell transplantation for severe multiple sclerosis. Blood 102 (2003) 2364-2372
13. Saccardi R., Mancardi G.L., Solari A., et al. Autologous HSCT for severe progressive multiple sclerosis in a multicenter trial: impact on disease activity and quality of life. Blood 105 (2005) 2601-2607
14. Burt R.K., Cohen B., Rose J., et al. Haematopoietic stem cell transplantation for multiple sclerosis. Arch Neurol 62 (2005) 860-864
15. Sun W., Popat U., Hutton G., et al. Characteristics of T-cell receptor repertoire and myelin-reactive T cells reconstituted from autologous haematopoietic stem-cell grafts in multiple sclerosis. Brain 127 (2004) 996-1008
16. Burt R.K., Marmont A., Oyama Y., et al. Randomized controlled trials of autologous haematopoietic stem cell transplantation for autoimmune diseases. Arthritis Rheum 54 (2006) 3750-3760
17. Shevchenko Y.L., Novik A.A., Ionova T.I., et al. Three strategies of high dose chemotherapy + autologous stem cell transplantation in autoimmune diseases. [abstract]. Bone Marrow Transplant 33 Suppl 1 (2004) 346
18. Novik A., Ionova T., Bisaga G., et al. Clinical and quality of life responses to high-dose chemotherapy plus autologous stem cell transplantation in patients with multiple sclerosis: two case reports. Cytotherapy 7 (2005) 363-367
19. Kurtzke J.F. Rating neurologic impairment in multiple sclerosis; an expanded disability status scale (EDSS). Neurology 33 (1983) 1444-1452
20. Tindall A., and Gratwohl A. Blood and marrow stem cell transplants in autoimmune disease: a consensus report written on behalf of the European League against Rheumatism (EURAR) and the European Group for Blood and Marrow transplantation (EBMT). Bone Marrow Transplant 19 (1997) 643-645
21. Comi G., Kappos I., Clanet M., et al. Guidelines for autologous blood and marrow stem cell transplantation in multiple sclerosis: a consensus report written on behalf of the European Group for Blood and Marrow Transplantation and the European Charcot Foundation. J Neurol 247 (2000) 376-382
22. Brenner M.K. Haematopoietic stem cell transplantation for autoimmune disease: limits and future potential. Best Pract Res Clin Haematol 17 (2004) 359-374
23. Saccardi R., Kozak T., Bocelli-Tyndall C., et al. Autoimmune Diseases Working Party of EBMT. Autologous stem cell transplantation for progressive multiple sclerosis: update of the European Group for Blood and Marrow Transplantation autoimmune diseases working party database. Mult Scler 12 (2006) 814-823
24. Muraro A.P., Douek D.C., Packer A., et al. Thymic output generates a new and diverse TCR repertoire after autologous stem cell transplantation in multiple sclerosis patients. J Exp Med 201 (2005) 805-816
25. Inglese M., Mancardi G.L., Pagani E., et al. Brain tissue loss occurs after suppression of enhancement in patients with multiple sclerosis treated with autologous haematopoietic stem cell transplantation. J Neurol Neurosurg Psychiatry 75 (2004) 643-644
26. Burt R.K., Padilla J., Begolka W.S., et al. Effect of disease stage on clinical outcome after syngeneic bone marrow transplantation for relapsing experimental autoimmune encephalomyelitis. Blood 91 (1998) 2609-2616
27. Burt R.K., Cohen B., Lobeck L., and Traynor A.E. Autologous haematopoietic stem cell transplantation in multiple sclerosis: importance of disease stage on outcome. [abstract]. Neurology 40 Suppl (2003) A150